While the IGHV mutational status does not vary throughout treatment and testing need not be repeated, it is important to re-assess the patient with RR CLL by karyotyping and fluorescence in situ hybridization (FISH), and sequencing of TP53 if no aberrations were found previously. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.